Abstract
Objectives
The number of hemodialysis patients requiring aortic valve replacement (AVR) is increasing. Although bioprosthetic valves are increasingly popular, they are associated with a risk of structural valve deterioration (SVD). The aim of this study is to examine the outcomes of bioprosthetic valves in hemodialysis patients undergoing AVR and to identify treatment strategies that can decrease the risk of SVD.
Methods
Between February 2010 and November 2019, 61 patients on hemodialysis underwent AVR using bioprosthetic valves at our hospital. Five patients died while still in the hospital. Kaplan–Meier estimates of overall survival and univariate Cox proportional hazards regression analyses were performed for the remaining 56 patients.
Results
During follow-up, there were six SVD events (10.7%) related to the bioprosthetic valves. The survival rate was 67.9% at 3 years and 39.5% at 5 years. In all SVD cases, SVD was caused by aortic stenosis. The mean interval between AVR and the discovery of SVD was 41.5 months. The SVD-free rate was 88.6% at 3 years and 65.3% at 5 years. Preoperative phosphorus levels are associated with SVD risk. High preoperative phosphorus concentration is associated with elevated SVD risk.
Conclusions
In this study, we determined that the risk of SVD can be influenced by preoperative phosphorus level. Strict control of the phosphorus concentration of hemodialysis patients may decrease structural valve deterioration after aortic valve replacement.
Similar content being viewed by others
References
Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg. 2008;85:1490–5.
Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, Modine T, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the EAPCI endorsed by the ESC and the EACTS. Eur Heart J. 2017;38:3382–90.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
VARC-3 WRITING COMMITTEE, Philippe G, Nicolo P, Maria CA, Tamim N, Rebecca TH, Philippe P, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. Ther Apher Dial. 2021;77:2717–46.
Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial. 2015;19:540–74.
Ohara T, Hashimoto Y, Matsumura A, Suzuki M, Isobe M. Accelerated progression and morbidity in patients with aortic stenosis on chronic dialysis. Circ J. 2005;69:1535–9.
Aljohani S, Alqahtani F, Almustafa A, Boobes K, Modi S, Alkhouli M. Trends and outcomes of aortic valve replacement in patients with end-stage renal disease on hemodialysis. Am J Cardiol. 2017;120:1626–32.
Nakatsu T, Minakata K, Tanaka S, Minatoya K. Intermediate-term outcomes of aortic valve replacement with bioprosthetic or mechanical valves in patients on hemodialysis. J Thorac Cardiovasc Surg. 2019;157:2177–86.
Okada N, Tajima K, Takami Y, Kato W, Fujii K, Hibino M, et al. Valve selection for the aortic position in dialysis patients. Ann Thorac Surg. 2015;99:1524–31.
Anselmi A, Flecher E, Chabanne C, Ruggieri VG, Langanay T, Corbineau H, et al. Long-term follow-up of bioprosthetic aortic valve replacement in patients aged ≤60 years. J Thorac Cardiovasc Surg. 2017;154:1534–41.
Chan PG, Sultan I, Gleason TG, Navid F, Kilic A. Mechanical versus bioprosthetic valves in patients on dialysis. J Thorac Dis. 2019;11(5):1996–2005.
Linefsky JP, O’Brien KD, Katz R, Boer LH, Barasch E, Jenny NS, et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol. 2011;58:291–7.
Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease—Mineral and bone disorder. Ther Apher Dial. 2013;17:247–88.
Acknowledgements
The authors would like to thank Chris Rowthorn (http://www.eibunkousei.net/) for English language proofreading.
Author information
Authors and Affiliations
Contributions
Seimei GO: Conceptualization; Data curation; Formal analysis; Writing-original draft. Tomokuni FURUKAWA: Data curation; Writing-review & editing. Kazunori YAMADA: Data curation. Shingo MOCHIZUKI: Data curation. Shinya TAKAHASHI: Supervision, Writing-review & editing.
Corresponding author
Ethics declarations
Conflict of interest
There are no undeclared conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Go, S., Furukawa, T., Yamada, K. et al. Strict control of phosphorus concentration of hemodialysis patients may decrease structural valve deterioration after aortic valve replacement. Gen Thorac Cardiovasc Surg 70, 547–552 (2022). https://doi.org/10.1007/s11748-021-01739-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-021-01739-6